123i-beta-cit
Small moleculeexperimentalImaging agent
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 1992 (NCT00132626)
Timeline
1990s
- Jan 1, 1992
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 123-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- 123i-beta-cit
- 123i-β-cit
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00387075 | Phase 2 | Nov 1, 2006 | Department of Defense, Institute for Neurodegenerative Disorders, Molecular NeuroImaging |
| NCT00315250 | Phase 2 | Jan 1, 2006 | Department of Defense, Institute for Neurodegenerative Disorders, Molecular NeuroImaging |
| NCT00096720 | Phase 2 | Feb 1, 2004 | Boehringer Ingelheim, Department of Defense, Institute for Neurodegenerative Disorders |
| NCT00129675 | Phase 2 | Feb 1, 2003 | Institute for Neurodegenerative Disorders, Molecular NeuroImaging |
| NCT00117819 | Phase 2 | Mar 1, 2001 | Albany Medical College, Indiana University, Institute for Neurodegenerative Disorders |
| NCT00132626 | Phase 2 | Sep 30, 1992 | Institute for Neurodegenerative Disorders, Molecular NeuroImaging, National Institutes of Health (NIH) |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institute for Neurodegenerative Disorders | Academic/Hospital | 6 | 6 | 1 | 1992 |
| Molecular NeuroImaging | For profit | 4 | 0 | 1 | 1992 |
| Department of Defense | Government | 3 | 0 | 1 | 2004 |
| Albany Medical College | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Boehringer Ingelheim | For profit | 1 | 0 | 1 | 2004 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2001 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 1992 |
7 organizations
Page 1 / 1